The global human microbiome therapeutics market size is expected to reach USD 1,544.6 million by 2027 according to a new study by Polaris Market Research. The report “Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, and Prescription Drugs); By Therapeutic Area (Autoimmune Disorders, Dental Disorders, Digestive and Gastrointestinal Disorders, Dermatological Disorders, Infectious Disease, Metabolic Disorders, Oncology, and Others); By Indication (Acne Vulgaris, Atopic Dermatitis, Clostridium difficile Infection, Colorectal Cancer, Diabetes, Inflammatory Bowel Disease (IBD), Lactose Intolerance, Lung Cancer, Non-alcoholic steatohepatitis (NASH), Obesity, and Coeliac Disease); By Approach (Small Molecule Therapies, Single Strain Whole Bacteria, Microbial Consortia, Genetically Modified Single Strain Bacteria, Phage Cocktail, and Microbial Ecosystems), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Microbiome refers to the residing micro-organisms genomes in the human body, particularly in the gut. The human body comprises more than 100 trillion microbes and around 2 million microbe genomes. These microbiota plays a significant role in the body’s physiological functions and includes viruses, bacteria, and fungi. Primarily it has Bacteroidetes (gram negative) and Firmicutes, commonly Clostridium and Lactobacillus sp. (gram positive). The majority of these are strict anaerobes, with fungi and archaebacteria comprising less than 1 per cent of the total population.
Download sample: https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market/request-for-sample
The global market is driven by an increased focus on microbiome based early diagnosis of diseases, increase in the prevalence of diseases due to dysbiosis, rising collaborations, and strongly funded government backed microbiome research projects. In November 2019, the Million Microbiome of Humans Project (MMHP) was launched in collaboration with France, Denmark, China, Latvia, Sweden and other countries to co-operate in meta-genomic research. The aim is to create the largest human microbiome database from analyzing more than one million samples gathered from reproductive tract, gut, skin, and other organs in the next few years.
Market participants such as Enterome Bioscience, Biotagenics, Seres Therapeutics, Oxidien Pharmaceuticals, LLC, BoobyBiome, 4D Pharma PLC, UBiome, Carbiotix, E.I. du Pont de Nemours and Company, Finch Therapeutics, GNUbiotics Sciences, ClearB Therapeutics, GoodBelly, GoodGut, Synlogic, Second Genome, 16S Technologies, 5QBD-Biotech, Vedanta Biosciences, Holobiome, Commense, Ferring Pharmaceuticals, Evelo Biosciences, CoreBiome, Igen Biolab Group, ViThera Pharmaceuticals, DermBiont, Hyggut, Embion Technologies, Lactobio, BiomX, Exeliom Biosciences, and LNC Therapeutics are some of the key players operating in the concerned market.
VID-19 is open, and dosing to start very soon. The company is world leader in the production of live bio-therapeutics (live microbiome used to cure disease). Its products are the orally delivered single strain bacteria, which are naturally present in the human gut.
Get Discount offer: https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market/request-for-discount-pricing
Polaris Market research has segmented the Human Microbiome Therapeutics market report on the basis of product, therapeutic area, indication, approach, and region
Human Microbiome Therapeutics Product Outlook (Revenue – USD Million, 2016 – 2027)
- Probiotics
- Prebiotics
- Medical Foods
- Prescription Drugs
Human Microbiome Therapeutic Area Outlook (Revenue – USD Million, 2016 – 2027)
- Autoimmune Disorders
- Dental Disorders
- Digestive and Gastrointestinal Disorders
- Dermatological Disorders
- Infectious Disease
- Metabolic Disorders
- Oncology
- Others
Human Microbiome Therapeutics Indication Outlook (Revenue – USD Million, 2016 – 2027)
- Acne Vulgaris
- Atopic Dermatitis
- Clostridium Difficile Infection
- Colorectal Cancer
- Diabetes
- Inflammatory Bowel Disease (IBD)
- Lactose Intolerance
- Lung Cancer
- Non-alcoholic steatohepatitis (NASH)
- Obesity
- Coeliac Disease
Human Microbiome Therapeutics Approach Outlook (Revenue – USD Million, 2016 – 2027)
- Small Molecule Therapies
- Single Strain Whole Bacteria
- Microbial Consortia
- Genetically Modified Single Strain Bacteria
- Phage Cocktail
- Microbial Ecosystems
Human Microbiome Therapeutics Regional Outlook (Revenue – USD Million, 2016 – 2027)
- North America
- U.S.
- Canada
- Europe
- France
- Germany
- UK
- Italy
- Netherlands
- Spain
- Austria
- Asia Pacific
- China
- India
- Japan
- Malaysia
- Australia
- South Korea
- Central & South America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Buy Now: https://www.polarismarketresearch.com/checkouts/6541
New York, NY 22 Oct 2020: The global human microbiome therapeutics market size is expected to reach USD 1,544.6 million by 2027 according to a new study by Polaris Market Research.
The report “Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, and Prescription Drugs); By Therapeutic Area (Autoimmune Disorders, Dental Disorders, Digestive and Gastrointestinal Disorders, Dermatological Disorders, Infectious Disease, Metabolic Disorders, Oncology, and Others); By Indication (Acne Vulgaris, Atopic Dermatitis, Clostridium difficile Infection, Colorectal Cancer, Diabetes, Inflammatory Bowel Disease (IBD), Lactose Intolerance, Lung Cancer, Non-alcoholic steatohepatitis (NASH), Obesity, and Coeliac Disease); By Approach (Small Molecule Therapies, Single Strain Whole Bacteria, Microbial Consortia, Genetically Modified Single Strain Bacteria, Phage Cocktail, and Microbial Ecosystems), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.Microbiome refers to the residing micro-organisms genomes in the human body, particularly in the gut.
The human body comprises more than 100 trillion microbes and around 2 million microbe genomes.
The majority of these are strict anaerobes, with fungi and archaebacteria comprising less than 1 per cent of the total population.
Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market/request-for-sampleThe global market is driven by an increased focus on microbiome based early diagnosis of diseases, increase in the prevalence of diseases due to dysbiosis, rising collaborations, and strongly funded government backed microbiome research projects.
In November 2019, the Million Microbiome of Humans Project (MMHP) was launched in collaboration with France, Denmark, China, Latvia, Sweden and other countries to co-operate in meta-genomic research.
The new Human Microbiome Market report offers a comprehensive study of the current scenario of the market including major market dynamics.
Also, it highlights the in-depth marketing research with the newest trends, drivers, and segments with reference to regional and country.
Further, this report profiles top key players and analyze their market share, strategic development, and other development across the world.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the Human Microbiome Market include Embion Technologies S.A, ENTEROME SA, Evelo Biosciences Inc., IGEN BIOLAB GROUP, 4D Pharma Plc., Ferring Pharmaceuticals, Gnubiotics Sciences, YSOPIA Bioscience, ViThera Pharmaceuticals Inc., Gnubiotics Sciences, Osel Inc., SECOND GENOME THERAPEUTICS, Immuron Ltd., OxThera AB, AOBiome, Vedanta Biosciences, Inc., Seres Therapeutics, Inc., Vedanta Biosciences, Inc., Finch Therapeutics Group, Inc., and Assembly Biosciences, Inc..
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Human Microbiome Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/human-microbiome-market/download-sampleMarket SegmentationThe broad Human Microbiome Market has been sub-grouped into the Product, Disease, Application, Technology Type and Region.
The strategists can gain a detailed insight and devise appropriate strategies to target specific market.
